<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: To explore the association between use of <z:chebi fb="0" ids="6801">metformin</z:chebi> or other <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs and the risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Using the United Kingdom-based General Practice Research Database (GPRD), we conducted a nested case-control analysis in patients with <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Cases had an incident diagnosis of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and up to 6 controls per case were matched on age, sex, calendar time, general practice, and number of years of active history in the GPRD prior to the index date </plain></SENT>
<SENT sid="3" pm="."><plain>Results were adjusted for multiple potential confounders </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: We identified 920 diabetic patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Mean age ± SD was 70.2 ± 8.6 years and 63.3% were male </plain></SENT>
<SENT sid="6" pm="."><plain>Extensive use (≥50 prescriptions) of <z:chebi fb="0" ids="6801">metformin</z:chebi> was associated with a slightly increased risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (adjusted OR = 1.43, 95% CI: 1.08-1.90) as compared with non use, with an adjustment of OR = 1.81 (95% CI: 1.25-2.62) in men and of 1.00 (95% CI: 0.63-1.58) in women </plain></SENT>
<SENT sid="7" pm="."><plain>Neither extensive use of <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> (adjusted OR = 0.79, 95% CI: 0.60-1.03) nor insulin (adjusted OR = 0.90, 95% CI: 0.63-1.28) were associated with an increased risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>A long-term history of <z:mp ids='MP_0002055'>diabetes</z:mp> (&gt;10 years) was not associated with a materially increased risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> compared with short-term <z:mp ids='MP_0002055'>diabetes</z:mp> duration (&lt;2 years; adjusted OR = 1.14, 95% CI: 0.90-1.46) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Use of <z:chebi fb="0" ids="6801">metformin</z:chebi> was linked to an increased risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in men </plain></SENT>
<SENT sid="10" pm="."><plain>Use of <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> or insulin was not associated with an altered risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Impact: <z:chebi fb="0" ids="6801">Metformin</z:chebi> does not prevent <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>